PSI CRO Launches A Global Phase 3 Rare Disease Trial
ZUG, Switzerland--(BUSINESS WIRE)--
PSI CRO, a full-service contract research organization, announced today the launch of a new global study in Polycythemia vera in collaboration with AOP Orphan. PSI is setting up this 100-patient open-label, multicenter study at 45 sites across 13 countries globally.
Help employers find you! Check out all the jobs and post your resume.